<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hypertrophic scarring and keloids following burn injuries</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hypertrophic scarring and keloids following burn injuries</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Hypertrophic scarring and keloids following burn injuries</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gerd G Gauglitz, MMS, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marc G Jeschke, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Amy S Colwell, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Collins, MD, PhD, FACS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 09, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1131243033"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Keloids and hypertrophic scars are aberrations of physiologic wound healing characterized by greater and more sustained extracellular matrix deposition. They may also develop following any insult to the deep dermis. </p><p>The early application of topical therapies is advocated for healed burns in an effort to prevent hypertrophic scarring, particularly for deep burn injuries or those that show signs of delayed healing. The role of pressure garment therapy is less clear. </p><p>Keloids and hypertrophic scars affect the patient's quality of life, both physically and psychologically, causing pain, pruritus, and contractures. As such, burn patients should be promptly referred to a surgeon experienced in burn care if the wound fails to begin reepithelialization by two weeks, or at the first sign of hypertrophic scarring. </p><p>The evaluation and treatment of keloids and hypertrophic scars that result from burn injury is reviewed here. The initial management of the burn wound is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/16320.html" rel="external">"Overview of the management of the severely burned patient"</a>.)</p><p class="headingAnchor" id="H3706740013"><span class="h1">INCIDENCE AND RISK FACTORS</span><span class="headingEndMark"> — </span>Hypertrophic scars occur in between 30 and 90 percent of patients following burns [<a href="#rid1">1-3</a>]. A longer time to heal (ie, prolonged inflammation at the wound site) is the most important risk factor [<a href="#rid2">2,4-6</a>]. As an example, in a retrospective review of 59 children and 41 adult burn patients, when the time to heal was between 14 and 21 days, one third developed hypertrophic scars [<a href="#rid4">4</a>]. However, when the burn wound healed after 21 days, 78 percent of patients developed hypertrophic scars. For this reason, as well as for reduction of other burn wound complications (eg, infection), early rather than later burn wound excision and grafting is preferred for deep burns. </p><p>During skin grafting, the use of mesh skin grafts with a high expansion ratio (&gt;1:2) may increase the risk for pathologic scarring but may be necessary in patients with extensive burns, where coverage is the priority. Use of dermal regeneration templates may improve aesthetic and functional outcomes. (See  <a class="medical medical_review" href="/z/d/html/16320.html" rel="external">"Overview of the management of the severely burned patient", section on 'Early burn excision and coverage'</a> and  <a class="medical medical_review" href="/z/d/html/14990.html" rel="external">"Overview of surgical procedures used in the management of burn injuries", section on 'Burn wound coverage'</a>.)</p><p>Other risks for hypertrophic scarring include deep full-thickness burns, location of wounding (shoulders, anterior chest, neck, upper arms, cheeks), darker skin tone, and wounding during puberty and pregnancy. Genetic susceptibility, as evidenced as a personal or family history of exuberant scars after injury, also contributes to excessive scar formation [<a href="#rid2">2,7,8</a>].</p><p class="headingAnchor" id="H2251306411"><span class="h1">CLINICAL ASSESSMENT</span></p><p class="headingAnchor" id="H4074290081"><span class="h2">Pathologic versus typical scarring</span><span class="headingEndMark"> — </span>Following skin injury, normal wound healing progresses through a series of defined phases, which ultimately restore skin integrity through the creation of a scar. Burn wounds can heal by primary or secondary intention (eg, skin grafts) depending on their depth and need for coverage. (See  <a class="medical medical_review" href="/z/d/html/15080.html" rel="external">"Basic principles of wound healing"</a>.)</p><p>Normal scars progress from immature and mature  (<a class="graphic graphic_table graphicRef95115" href="/z/d/graphic/95115.html" rel="external">table 1</a>). Mature scars are flat and essentially asymptomatic. Typically, the average time for scar maturity is 9 to 12 months. Thus, any scar less than one year old can be described as an immature scar. Immature scars may mature over time; however, some scars will develop symptoms (eg, pain, pruritus) and/or develop characteristics consistent with hypertrophic or keloid scars. It can be difficult to determine when an immature scar becomes a hypertrophic scar. There is a wide range of changes between the scar that becomes hypertrophic in the first few months after the burn is healed compared with the more severe hypertrophic scar that becomes disfiguring [<a href="#rid9">9,10</a>].</p><p>Excessive scars form as a result of aberrations of physiologic wound healing and may arise following any insult to the deep dermis [<a href="#rid11">11</a>]. The characteristics of the scar determine if it is developing into a keloid or a hypertrophic scar  (<a class="graphic graphic_table graphicRef95115" href="/z/d/graphic/95115.html" rel="external">table 1</a>) [<a href="#rid9">9,10,12-15</a>]. Histologically, hypertrophic scars and keloids contain an overabundance of dermal collagen. (See  <a class="medical medical_review" href="/z/d/html/5569.html" rel="external">"Keloids and hypertrophic scars", section on 'Diagnosis'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Hypertrophic scarring is defined as a scar raised above the skin level that remains within the confines of the original area of skin injury and appears to be due to an overproduction of collagen and an imbalance between the anabolic and catabolic phases of healing [<a href="#rid2">2,12,16</a>]. On histological examination, hypertrophic scars contain primarily type III collagen oriented parallel to the epidermal surface with abundant nodules containing myofibroblasts, large extracellular collagen filaments, and plentiful acidic mucopolysaccharides [<a href="#rid17">17</a>]. Hypertrophic scars can be linear or widespread. Those associated with burn wounds are predominantly widespread. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Keloids also rise above the skin level, but these extend beyond the margin of the initial skin injury. Minor keloids are those &lt;0.5 cm; larger keloids are termed major keloids. Keloid tissue is mostly composed of disorganized type I and III collagen containing pale-staining hypocellular collagen bundles with no nodules or excess myofibroblasts [<a href="#rid17">17,18</a>]. </p><p></p><p class="headingAnchor" id="H211168544"><span class="h2">Scar grade</span><span class="headingEndMark"> — </span>Many assessment tools are available for analysis of pathologic conditions of the skin; however, there is no general agreement on the most appropriate tools for evaluation of scar tissue [<a href="#rid19">19</a>].</p><p>Scars are graded based upon specific parameters that include pigmentation, vascularity, thickness, pliability, height or depression, patient acceptability, and comfort. A variety of measuring tools have been developed, including the Vancouver Scar Scale (VSS), the Visual Analog Scale (VAS), and the Patient and Observer Scar Assessment Scale (POSAS). </p><p class="bulletIndent1"><span class="glyph">●</span>Scar grading systems are generally used to quantify alterations in scar appearance during treatment, typically in a clinical research setting. Although individual scar rating scales and other available tools have value, they generally are lacking in terms of validity, clinical evidence, and fulfillment of clinometric requirements [<a href="#rid20">20-22</a>]. In addition, grading scales have acceptable consistency and reliability but have limited sensitivity and are at least partially subjective in nature [<a href="#rid20">20</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An advantage of the POSAS relative to other scales is the inclusion of patient assessment, which is considered an important aspect of scar evaluation [<a href="#rid22">22</a>]. The POSAS is also more consistent and reliable than the widely used VSS [<a href="#rid20">20,21</a>]. Given the natural course of scar improvement during healing, the use of any scale must include the parameter of time relative to initial scar formation or subsequent treatment intervention [<a href="#rid22">22</a>]. </p><p></p><p>For routine clinical practice, evaluation of scar size, thickness, symptom severity (eg, pain, itching), and patient concerns is advised before initiating any treatment plan. Subsequently, an intraindividual comparison between baseline and later time points is advised, and objective changes in scar height and volume after different treatment approaches can be noted, avoiding subjective influences on scar evaluation [<a href="#rid23">23</a>]. </p><p>Quantitative three-dimensional imaging is a promising method for quick and objective assessment and documentation of abnormal scars and their response to treatment within routine clinical practice. In one study, three-dimensional stereophotogrammetry was used to objectively quantify a mean scar volume reduction from 0.73 to 0.14 cc following intralesional therapy [<a href="#rid24">24</a>]. </p><p class="headingAnchor" id="H1331486827"><span class="h2">Quality of life</span><span class="headingEndMark"> — </span>Keloids affect the patient's quality of life, both physically and psychologically [<a href="#rid11">11,25,26</a>]. A complete assessment of the impact of the scars on the burn patient should include a quality of life assessment. Several tools have been specifically designed for patients with hypertrophic scars or keloids [<a href="#rid27">27-29</a>]. Validation of these tools have shown excellent correlation with pain, pruritus, and restriction of mobility. </p><p>The Dermatologic Life Quality Index (DLQI) has also been used to evaluate daily impairments of life quality of different scar types [<a href="#rid30">30</a>]. </p><p class="headingAnchor" id="H4242189838"><span class="h1">PREVENTIVE STRATEGIES AND THEIR EFFICACY</span><span class="headingEndMark"> — </span>Once the wounds are closed (ie, epithelium of the burned skin or skin graft is intact and stable), scar prevention should be initiated. Prevention of widespread hypertrophic scarring is more efficient than treatment of a scar once it has matured [<a href="#rid9">9,10</a>]. (See <a class="local">'Timing'</a> below.) </p><p>The treatments discussed below  (<a class="graphic graphic_table graphicRef95116" href="/z/d/graphic/95116.html" rel="external">table 2</a>) are used to prevent or reduce the risk of hypertrophic scarring or keloid formation in the fresh scar that develops following a partial-thickness, full-thickness, or deeper burn  (<a class="graphic graphic_figure graphicRef73309" href="/z/d/graphic/73309.html" rel="external">figure 1</a>). Some of these same treatments are also used to manage established hypertrophic scars and keloids. (See <a class="local">'Clinical algorithms'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span>Silicone sheet or gel or onion-extract-containing gel is applied after burn wound coverage or closure for approximately three to six months. (See <a class="local">'Silicone sheets and gel formulations'</a> below and <a class="local">'Onion extract gels'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Compression garments may be used as monotherapy or in combination with silicone gel or sheets for up to one year [<a href="#rid31">31</a>]. (See <a class="local">'Compression therapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If there is no improvement with either application, consideration should be given to pulsed-dye laser (PDL) therapy to reduce wound erythema or fractional ablational laser therapy to improve scar surface and pliability. (See <a class="local">'Laser therapy'</a> below.) </p><p></p><p class="headingAnchor" id="H4072672870"><span class="h2">Silicone sheets and gel formulations</span><span class="headingEndMark"> — </span>Silicone gel sheeting, a soft, slightly adherent, and semiocclusive covering, may prevent or reduce the formation of hypertrophic scars by decreasing the collagen remodeling phase of wound healing, although the exact mechanism is unclear [<a href="#rid2">2,32-35</a>]. It has been suggested that its effect is due to increased wound hydration [<a href="#rid36">36,37</a>]. Only immature scars should be treated with gels or gel sheets as mature burn scars have not been shown to respond [<a href="#rid32">32</a>].</p><p>Silicone sheets are applied starting approximately two weeks after burn wound closure for 12 to 24 hours per day for approximately 12 to 24 weeks [<a href="#rid38">38</a>]. Silicone products can be used in children and are not painful [<a href="#rid6">6</a>]. Side effects of silicone sheeting include local skin reactions, such as maceration and pruritus, which may necessitate temporary cessation [<a href="#rid32">32</a>]. In areas where silicone sheets will not conform to the shape or size of the burn wound, silicone gel can be used to reduce the risk of unpleasant scarring and erythema and to improve scar pliability [<a href="#rid39">39</a>]. </p><p>Most trials evaluating silicone sheets for prevention have been in the non-burn population. In a meta-analysis of five trials including 402 non-burn patients at risk for hypertrophic scarring (mostly patients with surgical wounds), the rate of abnormal scarring was lower with silicone gel sheeting compared with control, but the difference was not statistically significant (15 versus 21 percent; risk ratio [RR] 0.55, 95% CI 0.21-1.45) [<a href="#rid40">40</a>]. In a subgroup analysis of 51 "high-risk" patients (people who were prone to scarring), the rate of hypertrophic scarring was significantly lower in the silicone gel sheeting group (24 versus 54 percent; RR 0.46, 95% CI 0.21-0.98). Most of the trials included in the meta-analysis were judged to be at high risk of bias. </p><p>Among studies performed in burn-only patients [<a href="#rid31">31,41-44</a>], most include a small number of participants, have differing comparisons, and are poorly controlled [<a href="#rid32">32</a>]. Larger randomized trials are needed to confirm the benefits of silicone products as a prevention and treatment of hypertrophic scars following burns. </p><p class="headingAnchor" id="H1812604768"><span class="h2">Onion extract gels</span><span class="headingEndMark"> — </span>An alternative therapy to silicone is onion extract gel; however, the evidence supporting this therapy for prevention of scarring is inconclusive and conflicting, with most trials in non-burn populations [<a href="#rid40">40,45-49</a>]. In one small trial that compared onion extract with silicone products (gel, gel sheet), the cosmetic appearance of burn hypertrophic scars was worse with onion extract gel after six months from injury as measured by the Vancouver Scar Scale [<a href="#rid42">42</a>]. Nevertheless, onion-extract-containing scar gels are generally well tolerated and are used worldwide, alone or in combination, for the prevention of excessive scar formation post-burn. </p><p class="headingAnchor" id="H3052791005"><span class="h2">Compression therapy</span><span class="headingEndMark"> — </span>Pressure therapy, in the form of continuously worn garments, may decrease collagen synthesis by limiting the supply of blood, oxygen, and nutrients to the scar tissue and/or by increasing apoptosis [<a href="#rid11">11,50,51</a>]. Although the efficacy of pressure therapy remains unproven in clinical trials [<a href="#rid52">52-56</a>], the practice is supported by years of clinical experience as a routine component of burn management. In a systematic review and meta-analysis of six randomized controlled trials (316 patients), pressure garment therapy reduced scar height, though the difference was small and of questionable clinical significance (standardized mean difference -0.31, 95% CI -0.63 to 0.00) [<a href="#rid52">52</a>]. There were no differences in global scar appearance, vascularity, pliability, or color. Three trials examining the combined use of pressure and silicone sheets have conflicting results [<a href="#rid31">31,44,57</a>]. </p><p>We mostly use pressure garments after burns affecting the arms and legs, rarely on the trunk. The amount of pressure and the duration of the therapy are based upon observational studies. We advise continuous pressure of 15 to 40 mmHg for at least 23 hours per day for at least 12 months while the burn scar is actively remodeling, adjusted for patient comfort and effectiveness [<a href="#rid53">53,58</a>]. The duration of wearing garments can also be extended up to 24 months. A randomized trial that included 53 hypertrophic scars from 17 patients found that patients treated with pressure garments providing 20 to 25 mmHg of pressure had significant improvement in scar thickness and erythema compared with wounds treated with 10 to 15 mmHg of pressure [<a href="#rid54">54</a>]. </p><p>The use of compression therapy is limited by the ability to adequately fit the garment to the wounded area [<a href="#rid58">58</a>]. Specialized suits or bandages, sometimes with transparent plastic masks or pressure buttons, may be needed for special locations. Compliance is often reduced by patient discomfort and other side effects such as maceration, eczema, drainage, or odor emanating from the garment. </p><p class="headingAnchor" id="H3848650046"><span class="h2">Investigational therapies</span><span class="headingEndMark"> — </span>Investigational approaches include the use of gene transfer technology to promote wound healing to stimulate the granulation process, vascularization, and reepithelialization or the scar quality [<a href="#rid59">59,60</a>]. Additional studies are needed to define growth factor levels in different phases of wound healing and to elucidate the precise timing of gene expression or downregulation required to better augment wound healing and control scar formation [<a href="#rid61">61</a>]. </p><p class="headingAnchor" id="H1336259076"><span class="h1">GENERAL APPROACH TO TREATMENT</span><span class="headingEndMark"> — </span>There are no established criteria that identify patients as ideal candidates for treatment. Even patients with a personal history of keloid scarring from other events may be eligible for attempts at scar modification, but recurrence of excess scarring is more likely. (See <a class="local">'Incidence and risk factors'</a> above.)</p><p class="headingAnchor" id="H2375650667"><span class="h2">Goals</span><span class="headingEndMark"> — </span>Treatment goals should be individualized based upon symptoms (eg, pruritus, pain), functional impairment (eg, contracture, mechanical irritation), and aesthetics [<a href="#rid9">9,10,62</a>]. Marked improvement is the main goal of treatment. This should include scar volume reduction by 30 to 50 percent, symptom reduction &gt;50 percent, and/or sufficient satisfaction of the patient, which should be achieved after three to six treatments or after three to six months. </p><p class="headingAnchor" id="H627747598"><span class="h2">Timing</span><span class="headingEndMark"> — </span>The timing of treatment is an important component of scar modification. Clinical experience supports the observations that younger scars respond better to any treatment approach compared with matured scars. However, hypertrophic scars have a prolonged maturation phase, meaning that they may improve over a one-year period by themselves and can show significant flattening and softening [<a href="#rid63">63</a>]. Early intervention using minimal invasive treatments may be useful, but surgical interventions should generally be delayed for at least one year. After that, revision of hypertrophic scars or keloid scars that are not causing functional impairment can generally proceed electively. (See <a class="local">'Scar excision'</a> below.)</p><p>Any functional impairment due to scar contractures should be managed as soon as it is identified. Hypertrophic scar contractures involving joints should be released as early as possible, to improve mobility [<a href="#rid26">26,64</a>]. Keloids rarely cause contractures. (See <a class="local">'Contracture release'</a> below.) </p><p class="headingAnchor" id="H1322381477"><span class="h2">Principles of treatment</span><span class="headingEndMark"> — </span>A few general principles are fundamental to the optimal management of hypertrophic scars and keloids that develop following a burn injury. These include the following [<a href="#rid9">9,10,26,31,38,63,65</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Treatment cannot be standardized because of the many clinical variables relating to hypertrophic scar and keloid formation. These include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Scar location</p><p class="bulletIndent2"><span class="glyph">•</span>Patient age </p><p class="bulletIndent2"><span class="glyph">•</span>Type of scar</p><p class="bulletIndent2"><span class="glyph">•</span>Ethnic and genetic predisposition </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Personalized management is necessary using a combination of therapies to achieve the desired results. A patient history of scarring and prior treatment can help determine the likely effectiveness of specific treatments for that patient. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment options include silicone gel sheeting, other topical therapies, intralesional injection therapies, laser therapy, compression therapy, massage therapy, physical therapy, and surgical scar excision and reconstruction. No single method of scar treatment can provide scar reduction, improve function, and/or alleviate symptoms for every patient.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatmentis based upon the type or characteristics of the scar(s)  (<a class="graphic graphic_table graphicRef95115" href="/z/d/graphic/95115.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef95116" href="/z/d/graphic/95116.html" rel="external">table 2</a>) [<a href="#rid9">9,10,38</a>]. Smaller hypertrophic scars or keloid scars are candidates for injectables. Scars that involve a large surface area are better treated with silicone sheets or compression garments. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with painful or pruritic scars can be initially managed using preventive therapies to minimize excessive scarring, such as silicone gel sheeting, onion extract gel, or compression therapy. (See <a class="local">'Preventive strategies and their efficacy'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A trial of topical agents such as moisturizers and topical or intralesional corticosteroids may be useful. Antihistamines may be added to relieve pruritus [<a href="#rid9">9,10</a>]. (See  <a class="medical medical_review" href="/z/d/html/14989.html" rel="external">"Management of burn wound pain and itching", section on 'Treatment of pruritus'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If these measures are not successful at meeting the goals for treatment, additional options include laser therapy, or surgical scar revision and reconstruction. (See <a class="local">'Laser therapy'</a> below and <a class="local">'Radiation therapy'</a> below and <a class="local">'Surgery'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Postoperative radiotherapy or pharmacologic therapy using <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> (FU) or <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">triamcinolone</a> acetonide (TAC) following surgical scar revision and reconstruction may help prevent recurrence. (See <a class="local">'Intralesional pharmacologic therapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Special patient populations also require specific considerations for treatment. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Children – Most hypertrophic scars and keloids are managed with silicone-based topicals or sheets or pressure garments. Intralesional agents are generally avoided because children are susceptible to side effects that include lipoatrophy, blistering, and pain. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pregnant women – High-risk therapies (eg, FU, radiation therapy) are avoided. (See  <a class="medical medical_review" href="/z/d/html/14613.html" rel="external">"Radiation-related risks of imaging", section on 'Pregnant women'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Facial scars – Crystal suspensions (eg, TAC) are avoided as they increase the risk of lipoatrophy. </p><p></p><p class="headingAnchor" id="H4210345821"><span class="h1">EFFICACY OF TREATMENTS IN BURN SCARS</span></p><p class="headingAnchor" id="H584883662"><span class="h2">Intralesional pharmacologic therapy</span><span class="headingEndMark"> — </span>Intralesional pharmacologic treatments for the treatment of hypertrophic scarring and keloids include predominantly <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">triamcinolone</a> acetonide (TAC) and <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> (FU) [<a href="#rid9">9,10</a>]. Factors that influence reported outcomes include the length of follow-up, the nature of the scars being treated, and whether there was a control therapy for comparison [<a href="#rid9">9,10</a>]. The majority of trials are in non-burn populations. Additional high-quality studies in the burn population are needed to identify the optimal agents, dosing, and timing. (See  <a class="medical medical_review" href="/z/d/html/5569.html" rel="external">"Keloids and hypertrophic scars"</a> and  <a class="medical medical_review" href="/z/d/html/5569.html" rel="external">"Keloids and hypertrophic scars", section on 'Intralesional chemotherapeutic agents'</a>.)</p><p>Repeated injections of TAC (40 mg/mL), alone or in combination with other intralesional therapies, administered at weekly or monthly intervals for four to six months appear to improve burn scar characteristics [<a href="#rid66">66-69</a>]. Alternatively, intralesional FU (50 mg/mL) is another approach to treatment. Two trials [<a href="#rid66">66,70</a>] identified in a systematic review suggest that intralesional <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">verapamil</a> (2.5 mg/mL) may be as effective as TAC with fewer adverse effects [<a href="#rid71">71</a>]. However, in a later trial, recurrence rates for verapamil were higher when compared with TAC [<a href="#rid72">72</a>]. </p><p>Intralesional therapies have also been used in combination with each other and with other treatments for refractory lesions [<a href="#rid65">65,73,74</a>]. (See <a class="local">'Surgery'</a> below and <a class="local">'Other treatments'</a> below.)</p><p class="headingAnchor" id="H3485338798"><span class="h2">Surgery</span></p><p class="headingAnchor" id="H1465543550"><span class="h3">Contracture release</span><span class="headingEndMark"> — </span>Increased tension on burn wound margins can result in the development of hypertrophic scars. Early surgical release is the most promising option based upon our clinical experience. Effective release of wound tension can be achieved by using a Z- or W-plasty (not appropriate for immature hypertrophic scars), full- or split-thickness skin grafts, or local skin flaps [<a href="#rid38">38,75,76</a>]. The optimal approach depends upon the degree of tension, the surface area involved, and the individual preference and expertise of the surgeon. (See  <a class="medical medical_review" href="/z/d/html/6670.html" rel="external">"Z-plasty"</a> and  <a class="medical medical_review" href="/z/d/html/15118.html" rel="external">"Skin autografting"</a> and  <a class="medical medical_review" href="/z/d/html/114188.html" rel="external">"Overview of flaps for soft tissue reconstruction"</a>.)</p><p>Prior to early contracture release, an early intervention of anti-inflammatory agents or radiotherapy may reduce recurrence rates. Some experts advocate using TAC or FU initially to soften the scar tissue prior to contracture release. </p><p class="headingAnchor" id="H4057709762"><span class="h3">Scar excision</span><span class="headingEndMark"> — </span>Hypertrophic scar or keloid excision alone is not an effective approach, since recurrence rates are high, ranging from 45 to 100 percent [<a href="#rid38">38,77,78</a>]. Scar excision should only be used in conjunction with other treatments applied before or after (or both) scar excision to reduce the risk of excessive scar formation [<a href="#rid9">9,10</a>]. One preoperative approach that may reduce recurrence is to inject cortisone or FU prior to surgery until the keloid or hypertrophic scar is stabilized and then perform the surgery. This approach may be less effective in pediatric burns [<a href="#rid79">79</a>]. Another approach uses radiotherapy before and after keloid excision [<a href="#rid80">80</a>]. (See <a class="local">'Intralesional pharmacologic therapy'</a> above and <a class="local">'Other treatments'</a> below.)</p><p>It is hypothesized that performing surgery when the scar is inactive will help reduce recurrence. However, for hypertrophic scars and keloids that develop because of delayed wound healing (eg, deep dermal burn, burn wound infection), surgical excision with primary suture closure or coverage with a skin graft converts the site into a fresh wound, potentially reducing the likelihood of hypertrophic scar formation at that site [<a href="#rid38">38,81</a>]. </p><p class="headingAnchor" id="H2742434824"><span class="h2">Other treatments</span></p><p class="headingAnchor" id="H1570390093"><span class="h3">Laser therapy</span><span class="headingEndMark"> — </span>Several types of lasers have been used in the treatment of keloids and hypertrophic scars following burn injury, including the fractional CO<sub>2</sub> laser, pulsed-dye lasers (PDLs), and erbium or neodymium-doped yttrium aluminium garnet (erbium:YAG and Nd:YAG) lasers [<a href="#rid82">82</a>]. Laser treatment (particularly fractional ablation type), often in combination with local flap design and/or the application of intralesional agents, is increasingly being advocated [<a href="#rid83">83,84</a>]. Patient satisfaction is generally high. The principles of using lasers in burns and burn reconstruction is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/138411.html" rel="external">"Overview of lasers in burns and burn reconstruction"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>PDL therapy was the first to gain wide acceptance for the management of hypertrophic scars and keloids and is the standard of care in some major burn centers [<a href="#rid15">15</a>]. The primary mechanism of PDL therapy is destroying small blood vessels by photothermolysis. PDL treatments can improve the appearance and normalize the vascularity and pliability of postoperative scars. Both long- and short-pulse PDL treatments are safe and improve the quality and cosmetic appearance of new surgical scars [<a href="#rid85">85,86</a>]. However, PDL therapy appears to be more effective for preventing hypertrophic scars, rather than for treating established scars [<a href="#rid2">2,15</a>]. Nonoverlapping laser pulses at fluences ranging from 6.0 to 7.5 Joules/cm<sup>2 </sup>(J/cm<sup>2</sup>; 7 mm spot) or from 4.5 to 5.5 J/cm<sup>2</sup> (10 mm spot) are used for the treatment of hypertrophic scars and keloids [<a href="#rid87">87</a>]. Two to six treatment sessions are necessary to successfully improve scar color, height, pliability, and texture [<a href="#rid88">88</a>]. However, other authors have not been able to reproduce these findings [<a href="#rid89">89</a>]. Nevertheless, based upon the German guidelines on scarring [<a href="#rid38">38</a>], PDL can be used for reduction of erythema (eg, in fresh, highly vascularized, reddish scars) and may also be considered for improvement of severe pruritus. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The 532 nm Q-switched Nd:YAG laser and the 585 nm flashlamp-pumped pulsed dye laser (FLPDL) offer comparable and favorable results for the treatment of pigmented hypertrophic scars. The 532 nm Q-switched Nd:YAG laser may be preferred by patients distressed by the dark color of their scars [<a href="#rid90">90</a>]. In addition, the higher penetration depth of the 532 nm Q-switched Nd:YAG laser may be more suitable for thicker scars compared with PDL treatment. Multiple treatments every three to four weeks using an Nd:YAG laser (5 mm spot size diameter, 14 J/cm<sup>2</sup> energy density, 300 microsecond exposure time per pulse, and 10 Hz repetition rate) are effective for improving hypertrophic scars and keloids. The authors of one study suggest that the Nd:YAG laser is most suitable for keloids and hypertrophic scars that have just appeared and/or have remained small and thin [<a href="#rid91">91</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fractional lasers<strong> </strong>might play a promising role in the treatment of widespread burn scars. Improvements in both clinical and structural features of burn scars have been reported after fractional CO<sub>2</sub> laser procedures [<a href="#rid92">92-95</a>]. In a large prospective study, fractional CO<sub>2</sub> laser therapy improved the signs and symptoms of hypertrophic burn scars, as measured by objective and subjective instruments [<a href="#rid96">96</a>]. In another review, patient satisfaction with fractional CO<sub>2</sub> laser therapy was 96.7 percent [<a href="#rid97">97</a>]. Patients reported reductions in neuropathic pain, tightness (contracture), and pruritus after approximately three treatments. In one small study, although multiple treatment sessions were needed for completely satisfying results, a single treatment demonstrated significant improvement of Vancouver Scar Scale (VSS), Dermatologic Life Quality Index (DLQI) and Patient and Observer Scar Assessment Scale (POSAS) scores compared with baseline. Fractional lasers are also associated with significant surface relief improvements and reductions in scar firmness compared with untreated internal controls [<a href="#rid92">92</a>]. Regardless of these promising results, more in-depth studies are needed to evaluate clinical protocols before definite recommendations for settings and intervals in between treatment sessions can be made [<a href="#rid9">9</a>]. </p><p></p><p class="headingAnchor" id="H2259322774"><span class="h3">Radiation therapy</span><span class="headingEndMark"> — </span>Superficial X-rays, electron beams, and low- or high-dose-rate brachytherapy have been used with overall good results to reduce recurrence of hypertrophic scars in burn patients [<a href="#rid98">98-101</a>], excepting one report [<a href="#rid102">102</a>]. In general, radiotherapy in association with surgical excision is performed for selected patients with a high risk of recurrence (eg, dark skin type, multiple keloids, areas of high tension). </p><p>Electron beam irradiation should be started early (24 to 48 hours) after keloid excision. A total dose of usually 12 Gy in 6 or 10 fractions of 2 Gy applied daily or every second day is currently recommended by dermatologists [<a href="#rid38">38</a>].</p><p class="headingAnchor" id="H1688872659"><span class="h3">Cryotherapy</span><span class="headingEndMark"> — </span>Most data available for cryotherapy relate to intralesional cryosurgery for keloids [<a href="#rid98">98,103,104</a>]. The probe, which is inserted into the hypertrophic scar or keloid, is connected to a canister of liquid nitrogen, which causes the cryoneedle to freeze, thereby freezing the scar tissue from the inside out. An average reduction in scar volume of 51 percent can be achieved following a single cryotreatment. For widespread burn scars, this approach is very time consuming, which limits the usefulness of this therapy.</p><p>Spray cryotherapy can be used for hypertrophic scars or keloids and is frequently used in combination with intralesional pharmacologic therapies. When treatment is combined, cryotherapy should be performed prior to injections to soften the tissue and ease the injection [<a href="#rid105">105</a>]. </p><p class="headingAnchor" id="H901651151"><span class="h3">Massage therapy</span><span class="headingEndMark"> — </span>There is preliminary evidence to suggest that scar massage may improve hypertrophic burn scarring. Systematic reviews have identified eight studies suggesting improvements in scar characteristics and reduced pain and itching [<a href="#rid106">106-109</a>] but noting that the quality of evidence is poor and there is a lack of consistent and valid scar assessment tools [<a href="#rid110">110</a>]. (See <a class="local">'Clinical assessment'</a> above.)</p><p class="headingAnchor" id="H3879325493"><span class="h1">CLINICAL ALGORITHMS</span></p><p class="headingAnchor" id="H2269961647"><span class="h2">Immature scar, erythematous hypertrophic scar, minor keloid</span><span class="headingEndMark"> — </span>The first line of treatment for immature burn scars, erythematous hypertrophic burn scars, and minor keloids following burns includes  (<a class="graphic graphic_table graphicRef95116" href="/z/d/graphic/95116.html" rel="external">table 2</a>) [<a href="#rid111">111-113</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">Triamcinolone</a> acetonide (TAC) injections administered every three to four weeks up six times (ie, six months). TAC can be used alone or in combination with silicone gel or silicone sheets [<a href="#rid9">9,10,114</a>]. Occasionally, injections continue for six months and more, depending upon the response [<a href="#rid115">115</a>]. (See <a class="local">'Intralesional pharmacologic therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Combination of silicone gel or sheeting with monthly intralesional corticosteroid injections (10 to 40 mg/mL) [<a href="#rid9">9,10,38</a>]. (See <a class="local">'Silicone sheets and gel formulations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pressure dressings can be applied for approximately three weeks to reduce the risk of progression of keloids. (See <a class="local">'Compression therapy'</a> above.)</p><p></p><p>For burn scars that do not favorably respond to the first line of therapy, spray cryotherapy with TAC injections can be administered three to six times every four weeks, or intralesional cryotherapy can be attempted twice, which is usually used for older or larger keloids prior to injection to soften the tissue and ease the injection [<a href="#rid26">26</a>]. (See <a class="local">'Cryotherapy'</a> above.) </p><p>If response is still not adequate, the third-line management options include <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> (FU) with TAC every week until the scar is flattened, repeat intralesional cryotherapy, or a surgical excision with a silicone product. Intralesional FU is an effective modality to treat minor keloids [<a href="#rid116">116</a>]. (See <a class="local">'Intralesional pharmacologic therapy'</a> above.)</p><p>Persistent erythematous wounds are treated with pulsed dye laser (PDL). (See <a class="local">'Laser therapy'</a> above.)</p><p>Immature scars should not be excised unless there is evidence of functional impairment, increased tension on wound margins, or delayed epithelialization. Surgical excision alone is reserved for patients with minor keloids that cause significant functional impairment, increased tension on wound margins, or delayed epithelialization or who have failed other modalities. However, some patients request removal of the minor keloid rather than undergoing medical management. Given the potential for recurrence after surgical excision of minor keloids, patients should be counseled regarding their expectations and possible outcomes. In addition, partial excision of the keloid is preferred if full excision increases the risk of structural damage or deformity [<a href="#rid9">9,10</a>]. Response rates vary from 50 to 100 percent and recurrence rates from 9 to 50 percent [<a href="#rid77">77</a>]. Adverse events include dermal atrophy, telangiectasia, and pain at the injection site. In addition, excisions of a keloid scar may result in a longer scar than the original and can result in an even larger keloid [<a href="#rid77">77,78</a>]. (See <a class="local">'Scar excision'</a> above.)</p><p class="headingAnchor" id="H2210141688"><span class="h2">Widespread hypertrophic burn scar</span><span class="headingEndMark"> — </span>Widespread hypertrophic scars can be a challenge to manage, and, frequently, individualized counseling and treatment plans need to be developed to address issues that include function (eg, joints) and cosmesis. The treatment of widespread hypertrophic burn scars depends on whether tension is present in the wound  (<a class="graphic graphic_table graphicRef95116" href="/z/d/graphic/95116.html" rel="external">table 2</a>).</p><p>Hypertrophic scarring that results from excessive wound tension or a delay in healing (eg, infection) is optimally managed with surgical release and scar excision followed by use of silicone gel sheets [<a href="#rid9">9,10</a>]. (See <a class="local">'Silicone sheets and gel formulations'</a> above.)</p><p>Onion-extract-containing formulations may also be used, although the body of evidence is not robust. (See <a class="local">'Onion extract gels'</a> above.)</p><p>The use of pressure garments has been standard therapy for widespread hypertrophic burn scars for many years. (See <a class="local">'Compression therapy'</a> above.)</p><p>PDL therapy can be used to treat the erythema in widespread hypertrophic scars. If there is no improvement, ablative CO<sub>2</sub> fractional lasers may be a promising alternative approach.<sub> </sub>In general, the PDL target is the erythema, and eventually there is some improvement of pliability of the scar. With a CO<sub>2</sub> laser, small columns (ablative microscopic treatment zones) are created that lead to microscopic wounds from which the wound healing process is activated. The claim is that due to remodeling of the tissue architecture and a shift of different collagen subtypes, the scar is being improved. Fractional ablation laser techniques have the advantage of performing well on large plates of hypertrophic scar, a clinical problem that is otherwise difficult to manage. (See <a class="local">'Laser therapy'</a> above.)</p><p class="headingAnchor" id="H2391219439"><span class="h2">Refractory or recurrent major keloids</span><span class="headingEndMark"> — </span>Refractory or recurrent major keloids present a management challenge as they are often recalcitrant to treatment and have a high probability of recurrence if they are excised [<a href="#rid9">9,10,114,117</a>]. Treatment of recurrent keloids and hypertrophic scarring following apparently successful treatment is similar to initial therapy; however, subsequent treatment may be more aggressively approached or by using combination treatments. </p><p>Intralesional corticosteroid administration with or without intralesional or spray adjuvant cryotherapy is advocated as a first-line strategy for patients with refractory or recurrent keloids [<a href="#rid9">9,10</a>]. If this strategy is not effective within three to four months, transition to intralesional FU and TAC is suggested [<a href="#rid9">9,10,65,73,74,118</a>]. The author advocates spray cryotherapy and TAC for a major keloid from a burn. The regimen at a major burn center in Canada is to inject either FU in low doses of 10 mg/mL or high doses of 40 mg/mL using <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">triamcinolone</a> 40 mg/mL [<a href="#rid119">119</a>]. The injection is conducted every four weeks for three to six months.</p><p>Secondary and tertiary management options for refractory keloids include laser treatment and surgical excision with appropriate prophylactic intralesional therapy, or radiation therapy. Whenever possible, referral to a clinician with expertise in managing recurrent or refractory keloids is advised.</p><p class="headingAnchor" id="H3142917307"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/117752.html" rel="external">"Society guideline links: Care of the patient with burn injury"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/129724.html" rel="external">"Society guideline links: Keloids and hypertrophic scars"</a>.)</p><p class="headingAnchor" id="H1131243100"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical assessment</strong> – Classification of excessive burn scarring is important to management  (<a class="graphic graphic_table graphicRef95115" href="/z/d/graphic/95115.html" rel="external">table 1</a>). Mature scars are flat and essentially asymptomatic. Immature scars may mature over time; however, some scars will develop symptoms (eg, pain, pruritus) or develop characteristics consistent with a hypertrophic scar or keloid. (See <a class="local">'Pathologic versus typical scarring'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention of excessive burn scarring</strong> – Once the wounds are healed (ie, epithelium of the burned skin or skin graft is intact and stable; typically around two weeks after the injury), scar prevention measures should be initiated. For most patients, we suggest silicone sheeting or gel in combination with pressure therapy (if practical) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Onion extract is a reasonable alternative to silicone, but it may be less effective. Prevention measures should generally be continued for three months  (<a class="graphic graphic_table graphicRef95116" href="/z/d/graphic/95116.html" rel="external">table 2</a>). Use of compression therapy may be limited by patient discomfort and other side effects. (See <a class="local">'Preventive strategies and their efficacy'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Goals and treatment</strong> – The goals of treatment for established hypertrophic scars or keloids include reduction of scar volume by 30 to 50 percent, reduction of symptoms by &gt;50 percent, and/or sufficient patient satisfaction. These should be achieved after three to six treatments or after three to six months. In the absence of high-quality evidence in the burn population, our approach is as follows  (<a class="graphic graphic_table graphicRef95116" href="/z/d/graphic/95116.html" rel="external">table 2</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For immature burn scar, minor burn keloid, or erythematous hypertrophic burn scar, we suggest intralesional injections with <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">triamcinolone</a> acetonide and silicone sheeting or gel as the first line of management (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Pressure dressings can be applied for approximately three weeks to limit progression. (See <a class="local">'Immature scar, erythematous hypertrophic scar, minor keloid'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For widespread hypertrophic burn scars without associated tension, we suggest treatment with silicone sheeting or gel, or onion extract gel, and pressure therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Widespread hypertrophic burn scar'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For widespread hypertrophic burn scars associated with tension that limit function or cause contractures, we suggest surgical scar release and scar excision/revision with adjunctive use of silicone sheeting or gel, or onion extract gel, and pressure therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). For patients who are not responsive to therapy, we use ablative fractional laser therapy. (See <a class="local">'Widespread hypertrophic burn scar'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For major, refractory, or recurrent keloids, we suggest intralesional corticosteroids with adjuvant cryotherapy as a first-line strategy to reduce scar symptoms and volume (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). If treatment is not effective, we use multimodality therapy, which includes intralesional <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> and <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">triamcinolone</a> acetonide with spray cryotherapy, with or without pulsed-dye laser therapy. (See <a class="local">'Refractory or recurrent major keloids'</a> above.) </p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Arno AI, Gauglitz GG, Barret JP, Jeschke MG. Up-to-date approach to manage keloids and hypertrophic scars: a useful guide. Burns 2014; 40:1255.</a></li><li><a class="nounderline abstract_t">Bloemen MC, van der Veer WM, Ulrich MM, et al. Prevention and curative management of hypertrophic scar formation. Burns 2009; 35:463.</a></li><li><a class="nounderline abstract_t">Oosterwijk AM, Mouton LJ, Schouten H, et al. Prevalence of scar contractures after burn: A systematic review. Burns 2017; 43:41.</a></li><li><a class="nounderline abstract_t">Deitch EA, Wheelahan TM, Rose MP, et al. Hypertrophic burn scars: analysis of variables. J Trauma 1983; 23:895.</a></li><li><a class="nounderline abstract_t">Cubison TC, Pape SA, Parkhouse N. Evidence for the link between healing time and the development of hypertrophic scars (HTS) in paediatric burns due to scald injury. Burns 2006; 32:992.</a></li><li><a class="nounderline abstract_t">Berman B, Viera MH, Amini S, et al. Prevention and management of hypertrophic scars and keloids after burns in children. J Craniofac Surg 2008; 19:989.</a></li><li><a class="nounderline abstract_t">Lewis WH, Sun KK. Hypertrophic scar: a genetic hypothesis. Burns 1990; 16:176.</a></li><li><a class="nounderline abstract_t">Gauglitz GG, Kunte C. [Recommendations for the prevention and therapy of hypertrophic scars and keloids]. Hautarzt 2011; 62:337.</a></li><li><a class="nounderline abstract_t">Gold MH, Berman B, Clementoni MT, et al. Updated international clinical recommendations on scar management: part 1--evaluating the evidence. Dermatol Surg 2014; 40:817.</a></li><li><a class="nounderline abstract_t">Gold MH, McGuire M, Mustoe TA, et al. Updated international clinical recommendations on scar management: part 2--algorithms for scar prevention and treatment. Dermatol Surg 2014; 40:825.</a></li><li><a class="nounderline abstract_t">Gauglitz GG, Korting HC, Pavicic T, et al. Hypertrophic scarring and keloids: pathomechanisms and current and emerging treatment strategies. Mol Med 2011; 17:113.</a></li><li><a class="nounderline abstract_t">Peacock EE Jr, Madden JW, Trier WC. Biologic basis for the treatment of keloids and hypertrophic scars. South Med J 1970; 63:755.</a></li><li><a class="nounderline abstract_t">MANCINI RE, QUAIFE JV. Histogenesis of experimentally produced keloids. J Invest Dermatol 1962; 38:143.</a></li><li><a class="nounderline abstract_t">Muir IF. On the nature of keloid and hypertrophic scars. Br J Plast Surg 1990; 43:61.</a></li><li><a class="nounderline abstract_t">Brewin MP, Lister TS. Prevention or treatment of hypertrophic burn scarring: a review of when and how to treat with the pulsed dye laser. Burns 2014; 40:797.</a></li><li><a class="nounderline abstract_t">Brown JJ, Bayat A. Genetic susceptibility to raised dermal scarring. Br J Dermatol 2009; 161:8.</a></li><li><a class="nounderline abstract_t">Slemp AE, Kirschner RE. Keloids and scars: a review of keloids and scars, their pathogenesis, risk factors, and management. Curr Opin Pediatr 2006; 18:396.</a></li><li class="breakAll">Sephel GC, Woodward SC. Repair, regeneration, and fibrosis. In: Rubin's Pathology, 4th ed, Rubin E (Ed), Lippincott, Williams &amp; Wilkins, Baltimore 2001. p.84.</li><li><a class="nounderline abstract_t">van Zuijlen PP, Angeles AP, Kreis RW, et al. Scar assessment tools: implications for current research. Plast Reconstr Surg 2002; 109:1108.</a></li><li><a class="nounderline abstract_t">Fearmonti R, Bond J, Erdmann D, Levinson H. A review of scar scales and scar measuring devices. Eplasty 2010; 10:e43.</a></li><li><a class="nounderline abstract_t">Tyack Z, Simons M, Spinks A, Wasiak J. A systematic review of the quality of burn scar rating scales for clinical and research use. Burns 2012; 38:6.</a></li><li><a class="nounderline abstract_t">van der Wal MB, Verhaegen PD, Middelkoop E, van Zuijlen PP. A clinimetric overview of scar assessment scales. J Burn Care Res 2012; 33:e79.</a></li><li><a class="nounderline abstract_t">Gauglitz GG, Bureik D, Dombrowski Y, et al. Botulinum toxin A for the treatment of keloids. Skin Pharmacol Physiol 2012; 25:313.</a></li><li><a class="nounderline abstract_t">Ardehali B, Nouraei SA, Van Dam H, et al. Objective assessment of keloid scars with three-dimensional imaging: quantifying response to intralesional steroid therapy. Plast Reconstr Surg 2007; 119:556.</a></li><li><a class="nounderline abstract_t">Van Loey NE, Van Son MJ. Psychopathology and psychological problems in patients with burn scars: epidemiology and management. Am J Clin Dermatol 2003; 4:245.</a></li><li><a class="nounderline abstract_t">Gauglitz GG. Management of keloids and hypertrophic scars: current and emerging options. Clin Cosmet Investig Dermatol 2013; 6:103.</a></li><li><a class="nounderline abstract_t">Poetschke J, Schwaiger H, Gauglitz GG. Current and Emerging Options for Documenting Scars and Evaluating Therapeutic Progress. Dermatol Surg 2017; 43 Suppl 1:S25.</a></li><li><a class="nounderline abstract_t">Tyack Z, Ziviani J, Kimble R, et al. Measuring the impact of burn scarring on health-related quality of life: Development and preliminary content validation of the Brisbane Burn Scar Impact Profile (BBSIP) for children and adults. Burns 2015; 41:1405.</a></li><li><a class="nounderline abstract_t">Bock O, Schmid-Ott G, Malewski P, Mrowietz U. Quality of life of patients with keloid and hypertrophic scarring. Arch Dermatol Res 2006; 297:433.</a></li><li><a class="nounderline abstract_t">Poetschke J, Reinholz M, Schwaiger H, et al. DLQI and POSAS Scores in Keloid Patients. Facial Plast Surg 2016; 32:289.</a></li><li><a class="nounderline abstract_t">Steinstraesser L, Flak E, Witte B, et al. Pressure garment therapy alone and in combination with silicone for the prevention of hypertrophic scarring: randomized controlled trial with intraindividual comparison. Plast Reconstr Surg 2011; 128:306e.</a></li><li><a class="nounderline abstract_t">Nedelec B, Carter A, Forbes L, et al. Practice guidelines for the application of nonsilicone or silicone gels and gel sheets after burn injury. J Burn Care Res 2015; 36:345.</a></li><li><a class="nounderline abstract_t">Kuhn MA, Moffit MR, Smith PD, et al. Silicone sheeting decreases fibroblast activity and downregulates TGFbeta2 in hypertrophic scar model. Int J Surg Investig 2001; 2:467.</a></li><li><a class="nounderline abstract_t">Musgrave MA, Umraw N, Fish JS, et al. The effect of silicone gel sheets on perfusion of hypertrophic burn scars. J Burn Care Rehabil 2002; 23:208.</a></li><li><a class="nounderline abstract_t">Perkins K, Davey RB, Wallis KA. Silicone gel: a new treatment for burn scars and contractures. Burns Incl Therm Inj 1983; 9:201.</a></li><li><a class="nounderline abstract_t">Chang CC, Kuo YF, Chiu HC, et al. Hydration, not silicone, modulates the effects of keratinocytes on fibroblasts. J Surg Res 1995; 59:705.</a></li><li><a class="nounderline abstract_t">Gilman TH. Silicone sheet for treatment and prevention of hypertrophic scar: a new proposal for the mechanism of efficacy. Wound Repair Regen 2003; 11:235.</a></li><li><a class="nounderline abstract_t">Nast A, Eming S, Fluhr J, et al. German S2k guidelines for the therapy of pathological scars (hypertrophic scars and keloids). J Dtsch Dermatol Ges 2012; 10:747.</a></li><li><a class="nounderline abstract_t">Chernoff WG, Cramer H, Su-Huang S. The efficacy of topical silicone gel elastomers in the treatment of hypertrophic scars, keloid scars, and post-laser exfoliation erythema. Aesthetic Plast Surg 2007; 31:495.</a></li><li><a class="nounderline abstract_t">O'Brien L, Jones DJ. Silicone gel sheeting for preventing and treating hypertrophic and keloid scars. Cochrane Database Syst Rev 2013; :CD003826.</a></li><li><a class="nounderline abstract_t">van der Wal MB, van Zuijlen PP, van de Ven P, Middelkoop E. Topical silicone gel versus placebo in promoting the maturation of burn scars: a randomized controlled trial. Plast Reconstr Surg 2010; 126:524.</a></li><li><a class="nounderline abstract_t">Karagoz H, Yuksel F, Ulkur E, Evinc R. Comparison of efficacy of silicone gel, silicone gel sheeting, and topical onion extract including heparin and allantoin for the treatment of postburn hypertrophic scars. Burns 2009; 35:1097.</a></li><li><a class="nounderline abstract_t">Momeni M, Hafezi F, Rahbar H, Karimi H. Effects of silicone gel on burn scars. Burns 2009; 35:70.</a></li><li><a class="nounderline abstract_t">Harte D, Gordon J, Shaw M, et al. The use of pressure and silicone in hypertrophic scar management in burns patients: a pilot randomized controlled trial. J Burn Care Res 2009; 30:632.</a></li><li><a class="nounderline abstract_t">Beuth J, Hunzelmann N, Van Leendert R, et al. Safety and efficacy of local administration of contractubex to hypertrophic scars in comparison to corticosteroid treatment. Results of a multicenter, comparative epidemiological cohort study in Germany. In Vivo 2006; 20:277.</a></li><li><a class="nounderline abstract_t">Maragakis M, Willital GH, Michel G, Görtelmeyer R. Possibilities of scar treatment after thoracic surgery. Drugs Exp Clin Res 1995; 21:199.</a></li><li><a class="nounderline abstract_t">Chanprapaph K, Tanrattanakorn S, Wattanakrai P, et al. Effectiveness of onion extract gel on surgical scars in asians. Dermatol Res Pract 2012; 2012:212945.</a></li><li><a class="nounderline abstract_t">Jackson BA, Shelton AJ. Pilot study evaluating topical onion extract as treatment for postsurgical scars. Dermatol Surg 1999; 25:267.</a></li><li><a class="nounderline abstract_t">Chung VQ, Kelley L, Marra D, Jiang SB. Onion extract gel versus petrolatum emollient on new surgical scars: prospective double-blinded study. Dermatol Surg 2006; 32:193.</a></li><li><a class="nounderline abstract_t">Renò F, Sabbatini M, Lombardi F, et al. In vitro mechanical compression induces apoptosis and regulates cytokines release in hypertrophic scars. Wound Repair Regen 2003; 11:331.</a></li><li><a class="nounderline abstract_t">Baur PS, Larson DL, Stacey TR, et al. Ultrastructural analysis of pressure-treated human hypertrophic scars. J Trauma 1976; 16:958.</a></li><li><a class="nounderline abstract_t">Anzarut A, Olson J, Singh P, et al. The effectiveness of pressure garment therapy for the prevention of abnormal scarring after burn injury: a meta-analysis. J Plast Reconstr Aesthet Surg 2009; 62:77.</a></li><li><a class="nounderline abstract_t">Van den Kerckhove E, Stappaerts K, Fieuws S, et al. The assessment of erythema and thickness on burn related scars during pressure garment therapy as a preventive measure for hypertrophic scarring. Burns 2005; 31:696.</a></li><li><a class="nounderline abstract_t">Candy LH, Cecilia LT, Ping ZY. Effect of different pressure magnitudes on hypertrophic scar in a Chinese population. Burns 2010; 36:1234.</a></li><li><a class="nounderline abstract_t">Chang P, Laubenthal KN, Lewis RW 2nd, et al. Prospective, randomized study of the efficacy of pressure garment therapy in patients with burns. J Burn Care Rehabil 1995; 16:473.</a></li><li><a class="nounderline abstract_t">Engrav LH, Heimbach DM, Rivara FP, et al. 12-Year within-wound study of the effectiveness of custom pressure garment therapy. Burns 2010; 36:975.</a></li><li><a class="nounderline abstract_t">Li-Tsang CW, Zheng YP, Lau JC. A randomized clinical trial to study the effect of silicone gel dressing and pressure therapy on posttraumatic hypertrophic scars. J Burn Care Res 2010; 31:448.</a></li><li><a class="nounderline abstract_t">Macintyre L, Baird M. Pressure garments for use in the treatment of hypertrophic scars--a review of the problems associated with their use. Burns 2006; 32:10.</a></li><li><a class="nounderline abstract_t">Petrie NC, Vranckx JJ, Hoeller D, et al. Gene delivery of PDGF for wound healing therapy. J Tissue Viability 2005; 15:16.</a></li><li><a class="nounderline abstract_t">Rogers B, Lineaweaver WC. Skin wound healing and cell-mediated DNA transport. J Long Term Eff Med Implants 2002; 12:125.</a></li><li><a class="nounderline abstract_t">Gauglitz GG, Jeschke MG. Combined gene and stem cell therapy for cutaneous wound healing. Mol Pharm 2011; 8:1471.</a></li><li><a class="nounderline abstract_t">Finnerty CC, Jeschke MG, Branski LK, et al. Hypertrophic scarring: the greatest unmet challenge after burn injury. Lancet 2016; 388:1427.</a></li><li><a class="nounderline abstract_t">Reish RG, Eriksson E. Scar treatments: preclinical and clinical studies. J Am Coll Surg 2008; 206:719.</a></li><li><a class="nounderline abstract_t">Ogawa R, Akaishi S, Huang C, et al. Clinical applications of basic research that shows reducing skin tension could prevent and treat abnormal scarring: the importance of fascial/subcutaneous tensile reduction sutures and flap surgery for keloid and hypertrophic scar reconstruction. J Nippon Med Sch 2011; 78:68.</a></li><li><a class="nounderline abstract_t">Asilian A, Darougheh A, Shariati F. New combination of triamcinolone, 5-Fluorouracil, and pulsed-dye laser for treatment of keloid and hypertrophic scars. Dermatol Surg 2006; 32:907.</a></li><li><a class="nounderline abstract_t">Ahuja RB, Chatterjee P. Comparative efficacy of intralesional verapamil hydrochloride and triamcinolone acetonide in hypertrophic scars and keloids. Burns 2014; 40:583.</a></li><li><a class="nounderline abstract_t">Grisolia GA, Danti DA, Santoro S, et al. Injection therapy with triamcinolone hexacetonide in the treatment of burn scars in infancy: results of 44 cases. Burns Incl Therm Inj 1983; 10:131.</a></li><li><a class="nounderline abstract_t">Wang XQ, Liu YK, Qing C, Lu SL. A review of the effectiveness of antimitotic drug injections for hypertrophic scars and keloids. Ann Plast Surg 2009; 63:688.</a></li><li><a class="nounderline abstract_t">Trisliana Perdanasari A, Torresetti M, Grassetti L, et al. Intralesional injection treatment of hypertrophic scars and keloids: a systematic review regarding outcomes. Burns Trauma 2015; 3:14.</a></li><li><a class="nounderline abstract_t">Margaret Shanthi FX, Ernest K, Dhanraj P. Comparison of intralesional verapamil with intralesional triamcinolone in the treatment of hypertrophic scars and keloids. Indian J Dermatol Venereol Leprol 2008; 74:343.</a></li><li><a class="nounderline abstract_t">Verhiel S, Piatkowski de Grzymala A, van der Hulst R. Mechanism of Action, Efficacy, and Adverse Events of Calcium Antagonists in Hypertrophic Scars and Keloids: A Systematic Review. Dermatol Surg 2015; 41:1343.</a></li><li><a class="nounderline abstract_t">Danielsen PL, Rea SM, Wood FM, et al. Verapamil is Less Effective than Triamcinolone for Prevention of Keloid Scar Recurrence After Excision in a Randomized Controlled Trial. Acta Derm Venereol 2016; 96:774.</a></li><li><a class="nounderline abstract_t">Darougheh A, Asilian A, Shariati F. Intralesional triamcinolone alone or in combination with 5-fluorouracil for the treatment of keloid and hypertrophic scars. Clin Exp Dermatol 2009; 34:219.</a></li><li><a class="nounderline abstract_t">Davison SP, Dayan JH, Clemens MW, et al. Efficacy of intralesional 5-fluorouracil and triamcinolone in the treatment of keloids. Aesthet Surg J 2009; 29:40.</a></li><li><a class="nounderline abstract_t">Stekelenburg CM, Marck RE, Tuinebreijer WE, et al. A systematic review on burn scar contracture treatment: searching for evidence. J Burn Care Res 2015; 36:e153.</a></li><li><a class="nounderline abstract_t">Stekelenburg CM, Jaspers MEH, Jongen SJM, et al. Perforator-Based Interposition Flaps Perform Better Than Full-Thickness Grafts for the Release of Burn Scar Contractures: A Multicenter Randomized Controlled Trial. Plast Reconstr Surg 2017; 139:501e.</a></li><li><a class="nounderline abstract_t">Robles DT, Berg D. Abnormal wound healing: keloids. Clin Dermatol 2007; 25:26.</a></li><li><a class="nounderline abstract_t">Poochareon VN, Berman B. New therapies for the management of keloids. J Craniofac Surg 2003; 14:654.</a></li><li><a class="nounderline abstract_t">Patel PA, Bailey JK, Yakuboff KP. Treatment outcomes for keloid scar management in the pediatric burn population. Burns 2012; 38:767.</a></li><li><a class="nounderline abstract_t">Stahl S, Barnea Y, Weiss J, et al. Treatment of earlobe keloids by extralesional excision combined with preoperative and postoperative "sandwich" radiotherapy. Plast Reconstr Surg 2010; 125:135.</a></li><li><a class="nounderline abstract_t">Stiefel D, Schiestl C, Meuli M. Integra Artificial Skin for burn scar revision in adolescents and children. Burns 2010; 36:114.</a></li><li><a class="nounderline abstract_t">Willows BM, Ilyas M, Sharma A. Laser in the management of burn scars. Burns 2017; 43:1379.</a></li><li><a class="nounderline abstract_t">Leclère FM, Mordon SR. Twenty-five years of active laser prevention of scars: what have we learned? J Cosmet Laser Ther 2010; 12:227.</a></li><li><a class="nounderline abstract_t">Blome-Eberwein S, Gogal C, Weiss MJ, et al. Prospective Evaluation of Fractional CO2 Laser Treatment of Mature Burn Scars. J Burn Care Res 2016; 37:379.</a></li><li><a class="nounderline abstract_t">Nouri K, Rivas MP, Stevens M, et al. Comparison of the effectiveness of the pulsed dye laser 585 nm versus 595 nm in the treatment of new surgical scars. Lasers Med Sci 2009; 24:801.</a></li><li><a class="nounderline abstract_t">Nouri K, Elsaie ML, Vejjabhinanta V, et al. Comparison of the effects of short- and long-pulse durations when using a 585-nm pulsed dye laser in the treatment of new surgical scars. Lasers Med Sci 2010; 25:121.</a></li><li><a class="nounderline abstract_t">Tanzi EL, Alster TS. Laser treatment of scars. Skin Therapy Lett 2004; 9:4.</a></li><li><a class="nounderline abstract_t">Alster TS, Handrick C. Laser treatment of hypertrophic scars, keloids, and striae. Semin Cutan Med Surg 2000; 19:287.</a></li><li><a class="nounderline abstract_t">Paquet P, Hermanns JF, Piérard GE. Effect of the 585 nm flashlamp-pumped pulsed dye laser for the treatment of keloids. Dermatol Surg 2001; 27:171.</a></li><li><a class="nounderline abstract_t">Bowes LE, Nouri K, Berman B, et al. Treatment of pigmented hypertrophic scars with the 585 nm pulsed dye laser and the 532 nm frequency-doubled Nd:YAG laser in the Q-switched and variable pulse modes: a comparative study. Dermatol Surg 2002; 28:714.</a></li><li><a class="nounderline abstract_t">Akaishi S, Koike S, Dohi T, et al. Nd:YAG Laser Treatment of Keloids and Hypertrophic Scars. Eplasty 2012; 12:e1.</a></li><li><a class="nounderline abstract_t">Poetschke J, Dornseifer U, Clementoni MT, et al. Ultrapulsed fractional ablative carbon dioxide laser treatment of hypertrophic burn scars: evaluation of an in-patient controlled, standardized treatment approach. Lasers Med Sci 2017; 32:1031.</a></li><li><a class="nounderline abstract_t">Qu L, Liu A, Zhou L, et al. Clinical and molecular effects on mature burn scars after treatment with a fractional CO(2) laser. Lasers Surg Med 2012; 44:517.</a></li><li><a class="nounderline abstract_t">Ozog DM, Liu A, Chaffins ML, et al. Evaluation of clinical results, histological architecture, and collagen expression following treatment of mature burn scars with a fractional carbon dioxide laser. JAMA Dermatol 2013; 149:50.</a></li><li><a class="nounderline abstract_t">Suh DH, Chang, KY, et al. Revision of burn scars using ablative fractional CO2 laser. J Am Acad Dermatol 2012; 66:AB216.</a></li><li><a class="nounderline abstract_t">Hultman CS, Friedstat JS, Edkins RE, et al. Laser resurfacing and remodeling of hypertrophic burn scars: the results of a large, prospective, before-after cohort study, with long-term follow-up. Ann Surg 2014; 260:519.</a></li><li><a class="nounderline abstract_t">Levi B, Ibrahim A, Mathews K, et al. The Use of CO2 Fractional Photothermolysis for the Treatment of Burn Scars. J Burn Care Res 2016; 37:106.</a></li><li><a class="nounderline abstract_t">Ragoowansi R, Cornes PG, Moss AL, Glees JP. Treatment of keloids by surgical excision and immediate postoperative single-fraction radiotherapy. Plast Reconstr Surg 2003; 111:1853.</a></li><li><a class="nounderline abstract_t">Guix B, Henríquez I, Andrés A, et al. Treatment of keloids by high-dose-rate brachytherapy: A seven-year study. Int J Radiat Oncol Biol Phys 2001; 50:167.</a></li><li><a class="nounderline abstract_t">Escarmant P, Zimmermann S, Amar A, et al. The treatment of 783 keloid scars by iridium 192 interstitial irradiation after surgical excision. Int J Radiat Oncol Biol Phys 1993; 26:245.</a></li><li><a class="nounderline abstract_t">Sällström KO, Larson O, Hedén P, et al. Treatment of keloids with surgical excision and postoperative X-ray radiation. Scand J Plast Reconstr Surg Hand Surg 1989; 23:211.</a></li><li><a class="nounderline abstract_t">van de Kar AL, Kreulen M, van Zuijlen PP, Oldenburger F. The results of surgical excision and adjuvant irradiation for therapy-resistant keloids: a prospective clinical outcome study. Plast Reconstr Surg 2007; 119:2248.</a></li><li><a class="nounderline abstract_t">Berman B, Harrison-Balestra C, Perez OA, et al. Treatment of keloid scars post-shave excision with imiquimod 5% cream: A prospective, double-blind, placebo-controlled pilot study. J Drugs Dermatol 2009; 8:455.</a></li><li><a class="nounderline abstract_t">Cação FM, Tanaka V, Messina MC. Failure of imiquimod 5% cream to prevent recurrence of surgically excised trunk keloids. Dermatol Surg 2009; 35:629.</a></li><li><a class="nounderline abstract_t">Leventhal D, Furr M, Reiter D. Treatment of keloids and hypertrophic scars: a meta-analysis and review of the literature. Arch Facial Plast Surg 2006; 8:362.</a></li><li><a class="nounderline abstract_t">Cho YS, Jeon JH, Hong A, et al. The effect of burn rehabilitation massage therapy on hypertrophic scar after burn: a randomized controlled trial. Burns 2014; 40:1513.</a></li><li><a class="nounderline abstract_t">Roh YS, Seo CH, Jang KU. Effects of a skin rehabilitation nursing program on skin status, depression, and burn-specific health in burn survivors. Rehabil Nurs 2010; 35:65.</a></li><li><a class="nounderline abstract_t">Field T, Peck M, Scd, et al. Postburn itching, pain, and psychological symptoms are reduced with massage therapy. J Burn Care Rehabil 2000; 21:189.</a></li><li><a class="nounderline abstract_t">Silverberg R, Johnson J, Moffat M. The effects of soft tissue mobilization on the immature burn scar: results of a pilot study. J Burn Care Rehabil 1996; 17:252.</a></li><li><a class="nounderline abstract_t">Ault P, Plaza A, Paratz J. Scar massage for hypertrophic burns scarring-A systematic review. Burns 2018; 44:24.</a></li><li><a class="nounderline abstract_t">Zuber TJ, DeWitt DE. Earlobe keloids. Am Fam Physician 1994; 49:1835.</a></li><li><a class="nounderline abstract_t">Hatamipour E, Mehrabi S, Hatamipour M, Ghafarian Shirazi HR. Effects of combined intralesional 5-Fluorouracil and topical silicone in prevention of keloids: a double blind randomized clinical trial study. Acta Med Iran 2011; 49:127.</a></li><li><a class="nounderline abstract_t">Hassel JC, Löser C, Koenen W, et al. Promising results from a pilot study on compression treatment of ear keloids. J Cutan Med Surg 2011; 15:130.</a></li><li><a class="nounderline abstract_t">Monstrey S, Middelkoop E, Vranckx JJ, et al. Updated scar management practical guidelines: non-invasive and invasive measures. J Plast Reconstr Aesthet Surg 2014; 67:1017.</a></li><li><a class="nounderline abstract_t">Jalali M, Bayat A. Current use of steroids in management of abnormal raised skin scars. Surgeon 2007; 5:175.</a></li><li><a class="nounderline abstract_t">Haurani MJ, Foreman K, Yang JJ, Siddiqui A. 5-Fluorouracil treatment of problematic scars. Plast Reconstr Surg 2009; 123:139.</a></li><li><a class="nounderline abstract_t">Kelly AP. Medical and surgical therapies for keloids. Dermatol Ther 2004; 17:212.</a></li><li><a class="nounderline abstract_t">Nanda S, Reddy BS. Intralesional 5-fluorouracil as a treatment modality of keloids. Dermatol Surg 2004; 30:54.</a></li><li class="breakAll">http://sunnybrook.ca/content/?page=ross-tilley-burn-centre (Accessed on June 08, 2017).</li></ol></div><div id="topicVersionRevision">Topic 95111 Version 19.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24767715" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Up-to-date approach to manage keloids and hypertrophic scars: a useful guide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18951704" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Prevention and curative management of hypertrophic scar formation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27639820" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Prevalence of scar contractures after burn: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6632013" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Hypertrophic burn scars: analysis of variables.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16901651" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Evidence for the link between healing time and the development of hypertrophic scars (HTS) in paediatric burns due to scald injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18650721" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Prevention and management of hypertrophic scars and keloids after burns in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2383355" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Hypertrophic scar: a genetic hypothesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21468729" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : [Recommendations for the prevention and therapy of hypertrophic scars and keloids].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25068543" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Updated international clinical recommendations on scar management: part 1--evaluating the evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25068544" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Updated international clinical recommendations on scar management: part 2--algorithms for scar prevention and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20927486" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Hypertrophic scarring and keloids: pathomechanisms and current and emerging treatment strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5427162" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Biologic basis for the treatment of keloids and hypertrophic scars.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14469149" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Histogenesis of experimentally produced keloids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2310898" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : On the nature of keloid and hypertrophic scars.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24439925" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Prevention or treatment of hypertrophic burn scarring: a review of when and how to treat with the pulsed dye laser.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19508304" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Genetic susceptibility to raised dermal scarring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16914994" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Keloids and scars: a review of keloids and scars, their pathogenesis, risk factors, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16914994" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Keloids and scars: a review of keloids and scars, their pathogenesis, risk factors, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11884845" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Scar assessment tools: implications for current research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20596233" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : A review of scar scales and scar measuring devices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22047828" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A systematic review of the quality of burn scar rating scales for clinical and research use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22249102" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A clinimetric overview of scar assessment scales.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22948093" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Botulinum toxin A for the treatment of keloids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17230090" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Objective assessment of keloid scars with three-dimensional imaging: quantifying response to intralesional steroid therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12680803" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Psychopathology and psychological problems in patients with burn scars: epidemiology and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23637546" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Management of keloids and hypertrophic scars: current and emerging options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27153039" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Current and Emerging Options for Documenting Scars and Evaluating Therapeutic Progress.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26421693" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Measuring the impact of burn scarring on health-related quality of life: Development and preliminary content validation of the Brisbane Burn Scar Impact Profile (BBSIP) for children and adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16528552" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Quality of life of patients with keloid and hypertrophic scarring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27248027" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : DLQI and POSAS Scores in Keloid Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21921743" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Pressure garment therapy alone and in combination with silicone for the prevention of hypertrophic scarring: randomized controlled trial with intraindividual comparison.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25094007" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Practice guidelines for the application of nonsilicone or silicone gels and gel sheets after burn injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12678127" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Silicone sheeting decreases fibroblast activity and downregulates TGFbeta2 in hypertrophic scar model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12032371" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The effect of silicone gel sheets on perfusion of hypertrophic burn scars.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6831286" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Silicone gel: a new treatment for burn scars and contractures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8538169" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Hydration, not silicone, modulates the effects of keratinocytes on fibroblasts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12753606" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Silicone sheet for treatment and prevention of hypertrophic scar: a new proposal for the mechanism of efficacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22937806" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : German S2k guidelines for the therapy of pathological scars (hypertrophic scars and keloids).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17700980" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The efficacy of topical silicone gel elastomers in the treatment of hypertrophic scars, keloid scars, and post-laser exfoliation erythema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24030657" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Silicone gel sheeting for preventing and treating hypertrophic and keloid scars.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20679835" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Topical silicone gel versus placebo in promoting the maturation of burn scars: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19766399" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Comparison of efficacy of silicone gel, silicone gel sheeting, and topical onion extract including heparin and allantoin for the treatment of postburn hypertrophic scars.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18672332" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Effects of silicone gel on burn scars.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19506491" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The use of pressure and silicone in hypertrophic scar management in burns patients: a pilot randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16634531" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Safety and efficacy of local administration of contractubex to hypertrophic scars in comparison to corticosteroid treatment. Results of a multicenter, comparative epidemiological cohort study in Germany.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8846750" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Possibilities of scar treatment after thoracic surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22924037" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Effectiveness of onion extract gel on surgical scars in asians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10417579" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Pilot study evaluating topical onion extract as treatment for postsurgical scars.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16442038" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Onion extract gel versus petrolatum emollient on new surgical scars: prospective double-blinded study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12950636" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : In vitro mechanical compression induces apoptosis and regulates cytokines release in hypertrophic scars.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1003586" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Ultrastructural analysis of pressure-treated human hypertrophic scars.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18249046" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The effectiveness of pressure garment therapy for the prevention of abnormal scarring after burn injury: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15994014" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The assessment of erythema and thickness on burn related scars during pressure garment therapy as a preventive measure for hypertrophic scarring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20541324" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Effect of different pressure magnitudes on hypertrophic scar in a Chinese population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8537416" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Prospective, randomized study of the efficacy of pressure garment therapy in patients with burns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20537469" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : 12-Year within-wound study of the effectiveness of custom pressure garment therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20375696" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : A randomized clinical trial to study the effect of silicone gel dressing and pressure therapy on posttraumatic hypertrophic scars.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16413399" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Pressure garments for use in the treatment of hypertrophic scars--a review of the problems associated with their use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16302501" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Gene delivery of PDGF for wound healing therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12463069" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Skin wound healing and cell-mediated DNA transport.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21657247" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Combined gene and stem cell therapy for cutaneous wound healing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27707499" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Hypertrophic scarring: the greatest unmet challenge after burn injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18387479" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Scar treatments: preclinical and clinical studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21551963" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Clinical applications of basic research that shows reducing skin tension could prevent and treat abnormal scarring: the importance of fascial/subcutaneous tensile reduction sutures and flap surgery for keloid and hypertrophic scar reconstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16875473" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : New combination of triamcinolone, 5-Fluorouracil, and pulsed-dye laser for treatment of keloid and hypertrophic scars.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24182692" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Comparative efficacy of intralesional verapamil hydrochloride and triamcinolone acetonide in hypertrophic scars and keloids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6652538" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Injection therapy with triamcinolone hexacetonide in the treatment of burn scars in infancy: results of 44 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19887927" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : A review of the effectiveness of antimitotic drug injections for hypertrophic scars and keloids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27574660" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Intralesional injection treatment of hypertrophic scars and keloids: a systematic review regarding outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18797054" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Comparison of intralesional verapamil with intralesional triamcinolone in the treatment of hypertrophic scars and keloids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26606434" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Mechanism of Action, Efficacy, and Adverse Events of Calcium Antagonists in Hypertrophic Scars and Keloids: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26911400" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Verapamil is Less Effective than Triamcinolone for Prevention of Keloid Scar Recurrence After Excision in a Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19018794" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Intralesional triamcinolone alone or in combination with 5-fluorouracil for the treatment of keloid and hypertrophic scars.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19233005" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Efficacy of intralesional 5-fluorouracil and triamcinolone in the treatment of keloids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25051521" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : A systematic review on burn scar contracture treatment: searching for evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28121892" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Perforator-Based Interposition Flaps Perform Better Than Full-Thickness Grafts for the Release of Burn Scar Contractures: A Multicenter Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17276198" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Abnormal wound healing: keloids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14501323" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : New therapies for the management of keloids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22365616" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Treatment outcomes for keloid scar management in the pediatric burn population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20048606" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Treatment of earlobe keloids by extralesional excision combined with preoperative and postoperative "sandwich" radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19477602" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Integra Artificial Skin for burn scar revision in adolescents and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28784339" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Laser in the management of burn scars.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20825254" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Twenty-five years of active laser prevention of scars: what have we learned?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27828835" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Prospective Evaluation of Fractional CO2 Laser Treatment of Mature Burn Scars.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19572180" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Comparison of the effectiveness of the pulsed dye laser 585 nm versus 595 nm in the treatment of new surgical scars.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19662486" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Comparison of the effects of short- and long-pulse durations when using a 585-nm pulsed dye laser in the treatment of new surgical scars.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14716440" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Laser treatment of scars.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11149609" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Laser treatment of hypertrophic scars, keloids, and striae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11207693" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Effect of the 585 nm flashlamp-pumped pulsed dye laser for the treatment of keloids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12174064" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Treatment of pigmented hypertrophic scars with the 585 nm pulsed dye laser and the 532 nm frequency-doubled Nd:YAG laser in the Q-switched and variable pulse modes: a comparative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22259645" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Nd:YAG Laser Treatment of Keloids and Hypertrophic Scars.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28401348" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Ultrapulsed fractional ablative carbon dioxide laser treatment of hypertrophic burn scars: evaluation of an in-patient controlled, standardized treatment approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22907286" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Clinical and molecular effects on mature burn scars after treatment with a fractional CO(2) laser.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23069917" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Evaluation of clinical results, histological architecture, and collagen expression following treatment of mature burn scars with a fractional carbon dioxide laser.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Revision of burn scars using ablative fractional CO2 laser</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25115428" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Laser resurfacing and remodeling of hypertrophic burn scars: the results of a large, prospective, before-after cohort study, with long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26536539" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : The Use of CO2 Fractional Photothermolysis for the Treatment of Burn Scars.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12711944" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Treatment of keloids by surgical excision and immediate postoperative single-fraction radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11316560" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Treatment of keloids by high-dose-rate brachytherapy: A seven-year study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8491682" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : The treatment of 783 keloid scars by iridium 192 interstitial irradiation after surgical excision.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2617222" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Treatment of keloids with surgical excision and postoperative X-ray radiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17519728" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : The results of surgical excision and adjuvant irradiation for therapy-resistant keloids: a prospective clinical outcome study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19537368" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Treatment of keloid scars post-shave excision with imiquimod 5% cream: A prospective, double-blind, placebo-controlled pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19415792" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Failure of imiquimod 5% cream to prevent recurrence of surgically excised trunk keloids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17116782" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Treatment of keloids and hypertrophic scars: a meta-analysis and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24630820" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : The effect of burn rehabilitation massage therapy on hypertrophic scar after burn: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20306614" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Effects of a skin rehabilitation nursing program on skin status, depression, and burn-specific health in burn survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10850898" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Postburn itching, pain, and psychological symptoms are reduced with massage therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8736373" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : The effects of soft tissue mobilization on the immature burn scar: results of a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28669442" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Scar massage for hypertrophic burns scarring-A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8203321" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Earlobe keloids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21681697" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Effects of combined intralesional 5-Fluorouracil and topical silicone in prevention of keloids: a double blind randomized clinical trial study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21561580" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Promising results from a pilot study on compression treatment of ear keloids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24888226" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Updated scar management practical guidelines: non-invasive and invasive measures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17575671" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Current use of steroids in management of abnormal raised skin scars.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19116547" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : 5-Fluorouracil treatment of problematic scars.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15113289" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Medical and surgical therapies for keloids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14692928" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Intralesional 5-fluorouracil as a treatment modality of keloids.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
